TREM2 and Alzheimer disease: Activation of TREM2 signalling in transgenic AD mice models using humanized monoclonal IgG1 agonistic antibody AL002 normalized behavior [74], and this antibody successfully underwent phase I clinical trials (NCT03635047) and is currently in phase II (NCT04592874), which involves participants with early AD.